Summary of ProMIS Neurosciences FY Conference Call Company Overview - **Company**: ProMIS Neurosciences (NasdaqCM:PMN) - **Focus**: Development of novel drugs for Alzheimer's disease, specifically targeting amyloid beta oligomers Industry Insights - **Alzheimer's Disease Landscape**: - Current treatments have a risk-benefit profile that is not favorable, leading to challenges in prescription by physicians [2][3] - There is a significant opportunity for novel drugs that effectively target the harmful species of amyloid beta [3] Key Developments - **Clinical Trials**: - ProMIS is conducting a Phase 1b trial for its lead compound, PMN310, an amyloid beta monoclonal antibody [4][6] - The trial is on track for complete enrollment of 128 patients by the end of the year, with an interim analysis expected in Q2 of the following year [4][5][19] - Final top-line results are anticipated in Q4 of next year [5] Product Differentiation - **Targeting Strategy**: - PMN310 focuses on low molecular weight oligomers of amyloid beta, which are believed to be the most toxic and drive disease progression [10][14] - The industry has shifted away from targeting plaque forms of amyloid beta due to limited clinical benefits [9][10] Safety Profile - **Safety and Efficacy**: - The trial has shown a clean safety profile to date, with expectations to maintain low levels of ARIA (Amyloid-related imaging abnormalities) incidents [16][18] - The dropout rate in the trial is significantly lower than in other studies, indicating strong patient retention [15] Biomarker Analysis - **Interim Analysis**: - The interim analysis will focus on safety, biomarkers, and clinical endpoints, with specific biomarkers like pTau217 and neurogranin being key indicators of disease progression and neuroinflammation [20][21] - A recent study highlighted the predictive value of pTau217 for clinical outcomes, which may influence future regulatory considerations [22][25] Regulatory Considerations - **FDA Approval Pathway**: - The FDA has moved away from approving drugs based solely on plaque reduction, emphasizing the need for clinically validated endpoints [24][25] - There is uncertainty regarding whether pTau217 will be accepted as a valid biomarker for approval, as the FDA may continue to prioritize clinical endpoints [25][26] Future Directions - **Potential for Subcutaneous Delivery**: - The decision to pursue a subcutaneous formulation will likely be made after the interim analysis, depending on the efficacy and safety data [40][41] - The current formulation allows for monthly dosing, and if successful, a subcutaneous option could be developed in parallel with ongoing studies [41][42] Conclusion - ProMIS Neurosciences is positioned to potentially make significant contributions to the Alzheimer's treatment landscape with its innovative approach to targeting amyloid beta oligomers. The upcoming interim analysis and final results will be critical in determining the future trajectory of PMN310 and its market positioning.

Core Viewpoint - Promis Neurosciences (NASDAQ: PMN) is highlighted due to a price target of $18 set by H.C. Wainwright, indicating a potential price increase of approximately 50.5% from its current trading price of $7.21 [1][5] Group 1: Analyst Ratings - The stock has an average rating of "Moderate Buy" from four brokerages, with one sell rating and three buy ratings [2] - Recent analyst reports show a range of opinions, with Wall Street Zen downgrading the stock to "strong sell" and Weiss Ratings reaffirming a "sell (e+)" rating, while H.C. Wainwright and Guggenheim maintained "buy" ratings [3][5] Group 2: Stock Performance - PMN is currently priced at $7.08, reflecting an increase of approximately 4.86% or $0.33, with a trading range today between $6.51 and $7.40 [4] - Over the past year, PMN has experienced a high of $39.75 and a low of $6.27, with a market capitalization of around $9.25 million and a trading volume of 45,812 shares on NASDAQ [4]

Core Insights - ProMIS Neurosciences Inc. is advancing its clinical-stage biotechnology efforts with a focus on antibody therapeutics targeting neurodegenerative diseases, particularly Alzheimer's disease (AD) [1][8] - Recent analysis indicates that plasma phosphorylated tau (pTau181 and pTau217) can serve as a significant primary endpoint in early-stage AD clinical trials, potentially predicting clinical benefits [2][3] Group 1: Key Findings from the Publication - The analysis utilized data from several large monoclonal antibody trials in early AD, demonstrating that plasma pTau can effectively predict future clinical outcomes [3] - A strong predictive relationship was found, with treatment effects on plasma pTau at 6 months correlating approximately 0.78 with treatment effects on the Clinical Dementia Rating Sum of Boxes (CDR-SB) at 12 months [5] - The effect size on plasma pTau was about 2.6 times larger than that on CDR-SB, suggesting earlier and more robust detection of biomarker changes compared to clinical changes [5] Group 2: Implications for ProMIS and the PRECISE-AD Trial - ProMIS is conducting the PRECISE-AD trial, a Phase 1b study of PMN310, its lead amyloid-beta targeting antibody, in early AD patients [4][10] - The trial design incorporates plasma pTau as a central biomarker endpoint at 6 and 12 months, aligning with the publication's findings [6] - Simulations indicate that trials using plasma pTau as a primary endpoint may require as few as 100 participants, making them smaller and more efficient [5][6] Group 3: Mechanistic Fit for PMN310 - PMN310 is designed to neutralize toxic oligomers upstream of tau phosphorylation, which could lead to meaningful reductions in plasma pTau if successful [7] - The publication validates ProMIS's strategy of using sensitive plasma pTau biomarkers as a central element in the ongoing Phase 1b AD clinical trial [7] - The ability to link early plasma readouts to later clinical benefits allows for more informed decision-making regarding PMN310's development path [7]

Core Viewpoint - ProMIS Neurosciences, Inc. is actively engaging with investors and the healthcare community through participation in the 8th Annual Evercore Healthcare Conference, highlighting its focus on developing innovative therapies for Alzheimer's disease and other neurodegenerative disorders [1][2]. Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company dedicated to discovering and developing therapeutic antibodies and vaccines that target toxic oligomers associated with neurodegenerative diseases, including Alzheimer's disease, ALS, FTD, MSA, and PD [3]. - The company utilizes its proprietary EpiSelect™ target discovery engine to identify Disease Specific Epitopes (DSEs) on misfolded proteins, which are crucial for developing targeted therapies [3]. Product Development - PMN310 is the lead product candidate designed as a humanized monoclonal antibody that selectively targets toxic oligomers while avoiding plaque, potentially reducing the risk of amyloid-related imaging abnormalities (ARIA) [4]. - PMN310 received Fast Track designation from the U.S. FDA in July 2025, indicating its potential significance in treating Alzheimer's disease [4]. Clinical Trials - Following positive results from the Phase 1a trial, ProMIS initiated the PRECISE-AD Phase 1b clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's disease [5]. - The PRECISE-AD trial is designed as a randomized, double-blind, placebo-controlled study, focusing on the effects of PMN310 on biomarkers and clinical outcomes associated with Alzheimer's disease [5]. EpiSelect Drug Discovery Engine - The EpiSelect platform enables the identification of conformational epitopes on toxic misfolded proteins, facilitating the development of highly selective therapeutic antibodies and vaccines [6]. - PMN310 has demonstrated high selectivity for toxic amyloid-beta oligomers without significant reactivity with other forms, potentially minimizing adverse effects associated with conventional therapies [6].

Core Viewpoint - ProMIS Neurosciences Inc. has announced a one-for-twenty-five reverse stock split to comply with Nasdaq listing requirements and aims to increase the market price of its common shares [1][11]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern Time on November 28, 2025, with shares trading on a split-adjusted basis from that date [2]. - The number of outstanding common shares will decrease from approximately 53,811,110 shares to about 2,152,444 shares [3]. - Proportional adjustments will be made to equity incentive plans, stock options, and outstanding warrants in accordance with the reverse stock split [4]. Group 2: Compliance with Nasdaq - ProMIS received a deficiency letter from Nasdaq on January 8, 2025, indicating that its common shares had not maintained the minimum required closing bid price of at least $1.00 [8]. - The company was granted an additional 180-day compliance period until December 29, 2025, to regain compliance with the Bid Price Rule [10]. - The reverse stock split is part of the company's strategy to cure the deficiency and meet Nasdaq's listing standards [11]. Group 3: Shareholder Information - No fractional shares will be issued; shareholders entitled to fractional shares will receive cash instead [5]. - Stockholders with shares held in book-entry form or through a bank or broker will see the effects of the reverse stock split reflected in their accounts without needing to take action [6]. Group 4: Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative disorders, including Alzheimer's disease [13]. - The company utilizes its proprietary target discovery engine, EpiSelect™, to identify novel targets associated with misfolded proteins [13].

Financial Performance - Operating losses for the three months ended September 30, 2025, were $11.8 million, compared to $4.4 million for the same period in 2024, and for the nine months ended September 30, 2025, losses were $29.4 million, up from $10.8 million in 2024[112]. - The net loss for the nine months ended September 30, 2025, was $29.0 million, compared to a net income of $3.0 million in the same period of 2024, representing a decrease of $32.1 million[134]. - The net loss for the three months ended September 30, 2025, was $11.6 million, compared to a net income of $9.3 million in the same period of 2024, representing a decrease of $20.9 million[140]. - Other income decreased by $13.5 million for the nine months ended September 30, 2025, primarily due to a $17.0 million decrease in the gain on change in fair value of financial instruments[139]. Cash Flow and Funding - As of September 30, 2025, the accumulated deficit reached $119.7 million, with negative cash flows from operations of $18.8 million for the nine months ended September 30, 2025[112]. - The company expects cash of $15.4 million as of September 30, 2025, will not be sufficient to fund operations for at least 12 months, raising concerns about its ability to continue as a going concern[116]. - Cash provided by financing activities was $20.9 million for the nine months ended September 30, 2025, a decrease of $6.5 million compared to $27.4 million in the same period of 2024[158][159]. - The company reported a net increase in cash of $2.1 million for the nine months ended September 30, 2025, down from $8.9 million in the prior year[154]. - The company plans to seek additional funding through public and private financings, debt financings, collaboration agreements, strategic alliances, and licensing agreements to support future clinical activities[153]. Research and Development - PMN310, the lead product candidate, successfully completed its Phase 1a clinical trial and commenced the Phase 1b clinical trial ("PRECISE-AD") in December 2024, with plans to enroll approximately 100 subjects[116][117]. - Expenditures for PMN310 in the three and nine months ended September 30, 2025, were approximately $8.8 million and $21.5 million, respectively[120]. - PMN267, targeting ALS, is ready to progress to IND-enabling studies, subject to sufficient resources[121]. - PMN442, aimed at MSA and other synucleinopathies, has been humanized and is also ready for IND-enabling studies, pending resource availability[122]. - Research and development expenses increased by $17.7 million, or 280%, for the nine months ended September 30, 2025, compared to the same period in 2024, primarily due to a $17.0 million increase related to the PMN310 phase 1b trial[135]. - For the three months ended September 30, 2025, research and development expenses increased by $7.2 million, or 282%, compared to the same period in 2024, largely due to a $6.9 million increase related to the PMN310 trial[141]. Administrative Expenses - General and administrative expenses rose by $0.9 million, or 31%, for the nine months ended September 30, 2025, driven by a $0.5 million increase in employee salaries and benefits[138]. - General and administrative expenses for the three months ended September 30, 2025, increased by $0.1 million, or 4%, compared to the same period in 2024[142]. Shareholder Information - As of September 30, 2025, the total number of issued and outstanding Common Shares and Common Share Equivalents was 124,602,290[166]. - The company sold 1,019,877 Common Shares for net proceeds of $0.7 million during the three and nine months ended September 30, 2025[147]. - The company completed a private placement in July 2024 for aggregate gross proceeds of $30.3 million, selling 9,757,669 common share units at $2.15 each[148]. - The total aggregate gross proceeds from various offerings in July 2025 amounted to $21.6 million before deducting fees and offering expenses[152]. Liquidity and Risk - The company faces liquidity risk as a pre-revenue development stage company, relying on external fundraising to support operations[169]. - The company experienced a significant increase in accrued liabilities by $7.5 million and accounts payable by $2.5 million during the nine months ended September 30, 2025[155]. - There were no cash flows used in investing activities during the nine months ended September 30, 2025 or 2024[157]. - The company is classified as an "emerging growth company" under the JOBS Act, allowing it to delay adopting new accounting standards[164].

Financial Performance - Loss from operations for Q3 2025 was $11.8 million, compared to an operating loss of $4.4 million in Q3 2024, reflecting increased expenditures on clinical trials[11] - The net loss for Q3 2025 was $(11,580,126), contrasting with a net income of $9,275,825 in Q3 2024, indicating a shift of $20,855,951[17] - The total net loss for the nine months ended September 30, 2025, was $(29,045,059), compared to a net income of $3,017,080 for the same period in 2024[17] - The net loss per share, basic, for Q3 2025 was $(0.24), compared to a net income per share of $0.31 in Q3 2024[17] Research and Development - Research and development expenses for Q3 2025 were $9.8 million, a significant increase from $2.6 million in Q3 2024, primarily due to costs associated with the PRECISE-AD Phase 1b clinical trial for PMN310[11] - Research and development expenses for Q3 2025 reached $9,797,418, a significant increase from $2,563,774 in Q3 2024, representing a growth of 283%[17] Assets and Liabilities - Total current assets increased to $21.5 million as of September 30, 2025, compared to $18.9 million as of December 31, 2024[15] - Total liabilities rose to $12.3 million as of September 30, 2025, up from $2.4 million at the end of 2024, primarily due to increased accounts payable and accrued liabilities[15] - The accumulated deficit increased to $119.7 million as of September 30, 2025, compared to $90.7 million as of December 31, 2024[15] Clinical Trials and Product Development - PMN310, the lead candidate for Alzheimer's disease, is over 85% enrolled in the Phase 1b trial, with complete enrollment expected by the end of 2025[1] - The independent Data and Safety Monitoring Board recommended advancing to the third and final dose escalation cohort for PMN310 in the PRECISE-AD trial[5] - PMN310 has been granted Fast Track Designation by the U.S. FDA, indicating its potential to address significant unmet medical needs in Alzheimer's disease[3] - ProMIS is preparing for multiple key anticipated inflection points in 2026, including the reporting of interim data in Q2 2026 and final results in Q4 2026 for PMN310[2] Operating Expenses - Total operating expenses for Q3 2025 were $11,750,432, compared to $4,434,677 in Q3 2024, marking an increase of 165%[17] - General and administrative expenses for Q3 2025 were $1,953,014, slightly higher than $1,870,903 in Q3 2024, showing an increase of 4.4%[17] Shareholder Information - The weighted-average outstanding common shares, basic, increased to 48,833,799 in Q3 2025 from 30,023,675 in Q3 2024, an increase of 62%[17] Other Income - Total other income for Q3 2025 was $170,306, a decrease from $13,710,502 in Q3 2024, reflecting a decline of 98.76%[17]

Core Insights - ProMIS Neurosciences Inc. is advancing its lead candidate PMN310 for Alzheimer's disease, with over 85% enrollment in the Phase 1b PRECISE-AD trial and a favorable safety profile reported [1][6][8] - The company has successfully raised capital to support its strategic goals and has strengthened its board with the addition of a new member [2] - Financial results for Q3 2025 show an increase in cash reserves and a significant rise in research and development expenses due to the ongoing clinical trial [5][11] Alzheimer's Disease Program (PMN310) - PMN310 is a humanized IgG1 antibody targeting toxic AβO, which are believed to drive Alzheimer's disease [3][8] - The drug has received Fast Track Designation from the U.S. FDA, indicating its potential to address unmet medical needs in AD [3][8] - The ongoing PRECISE-AD trial is designed to evaluate the safety, tolerability, and pharmacokinetics of PMN310, with interim data expected in Q2 2026 and final results in Q4 2026 [1][9] Financial Highlights - As of September 30, 2025, ProMIS reported cash and cash equivalents of $15.4 million, up from $13.3 million at the end of 2024, primarily due to capital-raising activities [5] - Research and development expenses for Q3 2025 were $9.8 million, a significant increase from $2.6 million in the same period of 2024, reflecting the costs associated with the PRECISE-AD trial [11] - The company reported a loss from operations of $11.8 million for Q3 2025, compared to a loss of $4.4 million in Q3 2024, driven by increased trial expenditures [11][17] Key Pipeline Programs - PMN267, targeting toxic misfolded TDP-43 for amyotrophic lateral sclerosis (ALS), is ready to progress to IND-enabling studies [6] - PMN442, aimed at Parkinson's disease and multiple system atrophy, is also prepared to move forward to IND-enabling studies [6] Company Overview - ProMIS Neurosciences is focused on developing therapeutic antibodies for neurodegenerative diseases, utilizing its proprietary EpiSelect™ platform to identify disease-specific epitopes [7][10] - The company is headquartered in Cambridge, Massachusetts, and Toronto, Ontario, and is committed to addressing the challenges posed by misfolded proteins in various neurodegenerative conditions [7]

Summary of ProMIS Neurosciences FY Conference Call Company Overview - ProMIS Neurosciences is a publicly listed company on NASDAQ under the ticker PMN, focused on developing therapies for neurodegenerative diseases, particularly Alzheimer's disease [2][3] - The company is conducting a landmark 100-patient study with its lead monoclonal antibody, PMN310, targeting Alzheimer's disease [2][3] Core Points and Arguments Alzheimer's Disease Study - ProMIS is in the midst of a phase 1b study for Alzheimer's, with over 90% enrollment and data expected soon [3][26] - The study involves administering the drug over 12 months, with an interim analysis planned for mid-next year and final results expected by the end of next year [3][26] Unique Mechanism of Action - PMN310 selectively targets toxic oligomer forms of amyloid beta, which are believed to drive disease progression, rather than the plaque forms that previous therapies have targeted [4][5][7] - The company claims to be the only one with an antibody that selectively targets these toxic oligomers without binding to non-harmful forms [7][10] Differentiation from Competitors - ProMIS utilizes AI and advanced design techniques to create antibodies that specifically target misfolded proteins, a method that differs from competitors who have struggled with cross-reactivity to non-target forms [8][9][10] - Previous therapies targeting plaque have shown limited efficacy and significant side effects, such as ARIA (Amyloid-related imaging abnormalities) [6][12][15] Study Design and Expectations - The phase 1b study is designed to provide definitive answers regarding the drug's efficacy, with a focus on biomarkers, safety, and clinical signals [20][21] - The study aims to enroll 128 patients to ensure robust statistical outcomes, with a goal of moving directly to a phase 3 registration trial based on positive results [21][22] Biomarker Analysis - Key biomarkers being monitored include pTAU217, pTAU243, neurogranin, GFAP, SNAP25, and NFL, which are expected to show changes correlating with clinical outcomes [29][30] - The interim analysis will assess whether PMN310 is effectively engaging its target, with expectations of biomarker levels dropping if the drug is effective [30][31] Market and Strategic Insights - The company believes that reducing ARIA liability will significantly impact prescribing habits and patient confidence, enhancing revenue potential [36][39] - ProMIS has received interest from large pharmaceutical companies, indicating a positive outlook for partnerships and acquisitions in the Alzheimer's space [37][38] Future Outlook - The company anticipates that demonstrating improved safety and efficacy could shift the risk-benefit ratio favorably, benefiting both patients and shareholders [40][41] - ProMIS is positioned to potentially validate the oligomer hypothesis in Alzheimer's treatment, which could have significant implications for the industry [37][44] Other Important Content - The discussion highlighted the shift in understanding regarding the role of amyloid beta in Alzheimer's, moving away from plaque as the primary target to focusing on toxic oligomers [6][15] - The company emphasized the importance of a well-designed clinical study to provide credible evidence for its therapeutic approach [37][44]

Core Insights - ProMIS Neurosciences, Inc. is participating in the Guggenheim 2 Annual Healthcare Innovation Conference on November 10, 2025, where CEO Neil Warma will engage in a fireside chat and one-on-one investor meetings [1][2] Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapeutic antibodies and vaccines targeting toxic oligomers linked to neurodegenerative diseases, including Alzheimer's disease (AD) [3] - The company utilizes its proprietary EpiSelect™ platform to identify Disease Specific Epitopes (DSEs) on misfolded proteins, which are implicated in various neurodegenerative disorders such as AD, ALS, FTD, MSA, and PD [3] Product Development - PMN310 is the lead product candidate for AD, designed as a humanized monoclonal antibody that selectively targets toxic oligomers while avoiding plaque, potentially reducing amyloid-related imaging abnormalities (ARIA) [4] - PMN310 received Fast Track designation from the U.S. FDA in July 2025, indicating its potential for expedited development [4] Clinical Trials - Following positive results from the Phase 1a trial of PMN310, ProMIS initiated the PRECISE-AD Phase 1b clinical trial, which is a randomized, double-blind, placebo-controlled study assessing the safety, tolerability, and pharmacokinetics of multiple ascending doses of PMN310 in patients with Mild Cognitive Impairment and mild AD [5] - The PRECISE-AD trial aims to evaluate the effects of PMN310 on biomarkers associated with AD pathology and clinical outcomes, with a primary focus on safety and reduced risk of ARIA [5] Technology Platform - The EpiSelect platform developed by ProMIS Neurosciences identifies conformational epitopes on toxic misfolded proteins, enabling the generation of selective therapeutic antibodies and vaccines [6] - PMN310 has shown high selectivity for toxic amyloid-beta oligomers without significant reactivity with other forms, potentially minimizing risks associated with targeting vascular amyloid [6]